Obesity in Parkinson's disease patients on electrotherapy: collateral damage, adiposity rebound or secular trends?
Dulloo
Abdul G
AG
Department of Medicine/Physiology, University of Fribourg, Chemin du Musée 5, 1700 Fribourg, Switzerland. abdul.dulloo@unifr.ch
Montani
Jean-Pierre
JP
D000978:Antiparkinson Agents / Q000627:therapeutic use; D015992:Body Mass Index; D001921:Brain / Q000378:metabolism; D003131:Combined Modality Therapy; D004298:Dopamine / Q000378:metabolism; D004599:Electric Stimulation Therapy / Q000009:adverse effects*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D044342:Malnutrition / Q000378:metabolism; D009765:Obesity / Q000150:complications* / Q000378:metabolism; D010300:Parkinson Disease / Q000150:complications* / Q000378:metabolism / Q000628:therapy*; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D020531:Subthalamic Nucleus / Q000601:surgery
D000978:Antiparkinson Agents; D017448:Receptors, Dopamine D2; D007980:Levodopa; D004298:Dopamine